Acinetobacter News and Research

RSS

Nasopharyngeal microbiota influences SARS-CoV-2 infection status and severity

In a recent study posted to the medRxiv* pre-print server, Canadian researchers investigated how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection altered the microbiota composition of the host’s nasopharyngeal region.

16 Jun 2022

Study offers clues about the shift of harmless environmental bacterium to a dreaded pathogen

Hospital-acquired infections (HAIs) are often particularly difficult to treat because the pathogens have developed resistance to common antibiotics.

3 Jun 2022

Researchers focus on how bacterial cells adapt and resist antibiotics

Treatment of severe infections caused by pathogenic bacteria relies on ‘last resort’ antibiotics, but rising resistance by ‘superbugs’ to most clinically approved drugs leaves patients exposed to possible fatalities.

26 May 2022

Researchers discover how Acinetobacter baumannii can survive on hospital surfaces without water

The pathogen Acinetobacter baumannii can survive on hospital surfaces -; without water -; for months, an ability that has helped it become a leading cause of hospital-acquired infections.

2 May 2022

Automated system can offer great potential for the treatment of bloodstream infections

When treating acute infections in patients, health care providers must be able to quickly and accurately identify the best antibiotics for fighting the infection.

19 Apr 2022

Antimicrobial resistance in COVID-19

Researchers discuss the impact of this extensive use of antibiotics on the rise of antimicrobial resistance.

16 Mar 2022

Increasing trend of antimicrobial resistance in Eastern Mediterranean Region of World Health Organization

Researchers investigated the rising antimicrobial resistance in the Eastern Mediterranean Region of the World Health Organization from 2017 to 2019.

9 Mar 2022

Study establishes that a low dose SARS-CoV-2 infection increases risk of pneumococcal coinfection

A new study published on the bioRxiv* preprint server has evaluated bacterial susceptibility during SARS-CoV-2 infection.

3 Mar 2022

Altered microbiomes in SARS-CoV-2 infection pose threat of antibiotic resistance

A new study discusses changes in the microbiota of various parts of the body with SARS-CoV-2 infection.

27 Feb 2022

Structure of protein that can pump toxic molecules out of bacterial cells revealed

MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.

18 Feb 2022

Research project receives additional funding to tackle a drug-resistant superbug

A global drive - led by University of the West of Scotland (UWS) - to tackle a drug-resistant superbug has received additional funding.

14 Feb 2022

New compound could combat multidrug-resistant pathogens in healthcare settings

For years, public-health experts have been sounding the alarm about the next phase in humanity's co-existence with bacteria-;a dark future where emerging strains have rendered once-powerful antibiotics useless.

5 Jan 2022

Cheap and accessible methods for genome sequencing will help tackle future pandemics

A worldwide consortium of scientists, led by the Earlham Institute and the University of Liverpool in the UK, mark a significant milestone in equipping researchers in low- and middle-income countries (LMICs) with cheap and accessible methods for sequencing large collections of bacterial pathogens - at a cost of less than $10USD per genome.

21 Dec 2021

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg Pharma, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.

7 Dec 2021

Drug-resistant bacteria are quickly outpacing new antibiotic development

Experts predict that without intervention, the problem of multidrug-resistant bacterial infections could be catastrophic by 2050, killing nearly 10 million people each year.

24 Nov 2021

Machine learning approach effective in predicting antibiotic resistance spread

Genes aren't only inherited through birth. Bacteria have the ability to pass genes to each other, or pick them up from their environment, through a process called horizonal gene transfer, which is a major culprit in the spread of antibiotic resistance.

22 Oct 2021

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

The Global Antibiotic Research and Development Partnership, the Clinton Health Access Initiative and Shionogi & Co., Ltd today announced a Memorandum of Understanding to accelerate access, including in low- and middle-income countries, to the antibiotic cefiderocol for bacterial infections in patients with limited treatment options.

13 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Fish oil may help fight against superbugs

For the first time, Australian scientists have confirmed a link between the role of regular fish oil to break down the ability of 'superbugs' to become resistant to antibiotics.

9 Jun 2021

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021